In this webinar, we discuss a highly accurate assay for simultaneously measuring the concentration and binding of IgG, IgM, and IgA antibodies to the Receptor Binding Domain (RBD) of SARS-CoV-2. This new label-free assay provides, for the first time, detailed resolution of the immune response of patients recovering from COVID-19 in a single assay and represents a significant development for clinical research teams studying immune responses to SARS-CoV-2.
The results we share represent a breakthrough for testing four parameters simultaneously in a single automated experiment on sera from up to 384 patients, using just 2 µL of serum from each patient. The outcome of the research is important for screening the immune status of COVID-19 patients and will be of great interest for studying population immunity, vaccine efficacy, and the status of neutralizing antibodies.
Leon Terstappen, MD, PhD, Professor, University of Twente
Judicaël Parisot, PhD, Senior Applications Scientist, Carterra